Sickle Cell Disease Treatment Demonstration Program
We work with four regional teams from across the country to increase the number of providers treating persons for sickle cell disease or sickle cell related issues, increase the number of providers prescribing disease modifying therapies, such as hydroxyurea, and increase the number of patients receiving regular care from providers knowledgeable about treating sickle cell disease.
September 2014 to September 2017
- Who: Four regional grantee teams that cover diverse HRSA-designated regions across the country. Partnerships include sickle cell treatment centers, federally qualified health centers, community based organizations, parents and patients.
- Funder: The project is funded by the Health Resources and Services Administration.
- Our Role: Gather data from and evaluate the performance of SCDTDP grantees in addressing the goals of the program. Deliver a comprehensive report to congress that outlines results of the project, develop a model protocol that outlines strategies for improving sickle cell care, and establish a compendium of tools and materials developed by teams.
Creating Better Advocates for Sickle Cell Disease Care
Quality improvement in public health means working through every sector and influence that affects how people live. At the highest level, this includes the rules and laws where people live. Read how Missouri is creating better care for individuals with sickle cell disease by working with the state government to make change.
Sickle Cell Disease Treatment Demonstration Program 2017 Model Protocol
The purpose of this 2017 model protocol is to provide clinicians, nurses, allied health professionals, community-based organizations and public health agencies with recommendations and strategies to improve care provided to individuals with sickle cell disease and trait.
Sickle Cell Disease Treatment Demonstration Program Compendium of Tools and Materials
This compendium identifies promising practices and strategies used by participants in the Sickle Cell Disease Treatment Demonstration Program (SCDTDP) to implement changes in their health systems related to improving access to care, increasing use of hydroxyurea and provider education.
The following flyers were created for regional coordinating centers to use to talk about their involvement in the project and the project's impact:
ECHO flyer: This flyer shares information about the use of Project ECHO to expand the number of providers able to treat patients with sickle cell disease.
Impact Flyer: This flyer provides a high-level look at the SCDTDP and its impact nationwide.